Shares of OS Therapies Inc (NYSE:OSTX – Get Free Report) fell 0.9% on Monday . The stock traded as low as $2.99 and last traded at $2.99. 23,802 shares changed hands during mid-day trading, a decline of 87% from the average session volume of 180,573 shares. The stock had previously closed at $3.02.
Analyst Ratings Changes
Several equities research analysts have recently commented on the company. Brookline Capital Management raised OS Therapies to a “strong-buy” rating in a research note on Thursday, August 22nd. EF Hutton Acquisition Co. I upgraded OS Therapies to a “strong-buy” rating in a research report on Tuesday, September 3rd.
Check Out Our Latest Report on OSTX
OS Therapies Stock Performance
OS Therapies (NYSE:OSTX – Get Free Report) last posted its earnings results on Wednesday, August 14th. The company reported ($0.26) earnings per share (EPS) for the quarter. On average, equities research analysts anticipate that OS Therapies Inc will post -0.47 earnings per share for the current year.
About OS Therapies
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
See Also
- Five stocks we like better than OS Therapies
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for OS Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OS Therapies and related companies with MarketBeat.com's FREE daily email newsletter.